Five years after settling, GSK is again accused of breaching the Jemperli deal.
ApexOnco Front Page
Recent articles
Arcellx and AstraZeneca take centre stage.
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
Ocular toxicities could be the reason.
The group cans ZW171 after “on-target, off-tumour toxicity”.
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
As pivotal data approach, the French group pays $210m for ex-US rights.
Duality takes its Adam9-targeting conjugate into the clinic.
